Skip to content

ProQR Therapeutics N.V.

PRQR

CIK 0001612940

← back to feed
Revenue (TTM)
€15.97M
FY Dec 2025
Net Income (TTM)
−€41.37M
−51.9% YoY FY Dec 2025
EPS Diluted (TTM)
−€0.42
−25.0% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
-269.7%
FY Dec 2025
Net Margin
-259.1%
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
€92.41M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
105.36M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings